Interview: What Does Breakthrough Designation Mean For Manus Neurodynamica?
Executive Summary
Medtech Insight spoke to Rutger Zietsma, Manus Neurodynamica’ CEO, to learn about the next commercial steps for the company's Neuromotor Pen for differential diagnosis of neuromotor impairment.